- Conditions
- Schizophrenia, Major Depressive Disorder, Bipolar I Disorder
- Interventions
- Aripiprazole + IEM (Ingestible Event Marker)
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 4
- States / cities
- Granada Hills, California • Rochester, New York • Durham, North Carolina + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 79
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Schizophrenia
- Interventions
- PF-05180999, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Bipolar I Disorder, Bipolar II Disorder, Schizo Affective Disorder, Obesity, Weight Loss, GLP - 1
- Interventions
- Group Therapy Program, semaglutide, Phentermine-Topiramate, naltrexone and bupropion (combination)
- Behavioral · Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Schizophrenia, Psychotic Disorders
- Interventions
- Dimethoxybenzylidene anabaseine (DMXB-A), Placebo
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Schizophrenia
- Interventions
- PF-04802540, Placebo
- Drug
- Lead sponsor
- Taisho Pharmaceutical Co., Ltd.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Schizophrenia
- Interventions
- Brexpiprazole, OPDC-34712
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 2
- States / cities
- Garden Grove, California • San Diego, California
- Conditions
- Tobacco Dependence
- Interventions
- Varenicline, Placebo
- Drug
- Lead sponsor
- Brown University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Schizophrenia Disorders
- Interventions
- Placebo (single and multiple doses), AQW051 2 mg (single and multiple doses), AQW051 15mg (single and multiple doses), AQW051 100mg (single dose), and 50mg (multiple doses)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 2
- States / cities
- Glendale, California • Willingboro, New Jersey
- Conditions
- Schizophrenia or Schizoaffective Disorder
- Interventions
- AMG 581, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Schizophrenia
- Interventions
- Risperidone ISM® 100 mg, Risperdal 4mg Tablet
- Drug
- Lead sponsor
- Rovi Pharmaceuticals Laboratories
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 4
- States / cities
- Garden Grove, California • Gaithersburg, Maryland • Berlin, New Jersey + 1 more
- Conditions
- Schizophrenia
- Interventions
- ITI-214 Dose A, ITI-214 Dose B, ITI-214 Dose C, ITI-214 Dose D (Elderly), Placebo, ITI-214 Dose E, ITI-214 Dose F, ITI-214 Dose G, ITI-214 Dose H
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 2
- States / cities
- Glendale, California • New York, New York
- Conditions
- Schizophrenia
- Interventions
- Aripiprazole
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 3
- States / cities
- Little Rock, Arkansas • San Diego, California • Austin, Texas
- Conditions
- Suicide, Psychosis
- Interventions
- Cognitive Behavioral Suicide Prevention for psychosis CBSPp)
- Behavioral
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Schizophrenia, Schizoaffective, Bipolar Disorder 1
- Interventions
- Yoga-based Exercise (YE), Wellness Lifestyle Program (WLP)
- Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Cognitive Function 1, Social
- Interventions
- Social Cognition Assessment and Training
- Behavioral
- Lead sponsor
- The University of Texas at Dallas
- Other
- Eligibility
- 17 Years to 40 Years
- Enrollment
- 153 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2018
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar 1 Disorder
- Interventions
- clozapine, risperidone
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 524 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 5
- States / cities
- Hartford, Connecticut • Athens, Georgia • Chicago, Illinois + 2 more
- Conditions
- Schizophrenia
- Interventions
- Aripiprazole Lauroxil
- Drug
- Lead sponsor
- Alkermes, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 16
- States / cities
- Little Rock, Arkansas • Cerritos, California • Garden Grove, California + 13 more
- Conditions
- Schizophrenia
- Interventions
- APN1125, Placebo
- Drug
- Lead sponsor
- CoMentis
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Schizophrenia Spectrum and Other Psychotic Disorders, Schizophrenia, Delusional Disorder, Bipolar 1 Disorder, Schizoaffective Disorder, Psychosis Not Otherwise Specified, Early Psychosis
- Interventions
- Not listed
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 6
- States / cities
- Hartford, Connecticut • Athens, Georgia • Chicago, Illinois + 3 more
- Conditions
- Cognitive Impairment, Schizophrenia
- Interventions
- Eltoprazine, Placebo
- Drug
- Lead sponsor
- Amarantus BioScience Holdings, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Chicago, Illinois • Catonsville, Maryland + 3 more
- Conditions
- Schizophrenia, Bipolar I Disorder
- Interventions
- Iloperidone
- Drug
- Lead sponsor
- Vanda Pharmaceuticals
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 11
- States / cities
- Dothan, Alabama • Little Rock, Arkansas • Denver, Colorado + 7 more
- Conditions
- SCHIZOPHRENIA 1 (Disorder), Schizo Affective Disorder
- Interventions
- transcranial direct current stimulation, Sham stimulation
- Device
- Lead sponsor
- Nathan Kline Institute for Psychiatric Research
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Orangeburg, New York
- Conditions
- Schizophrenia
- Interventions
- SEP-380135, Quinidine Gluconate
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Healthy Volunteers, Schizophrenia
- Interventions
- TAK-041, TAK-041 Placebo
- Drug
- Lead sponsor
- Neurocrine Biosciences
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 114 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Glendale, California